world
6 known investors
FORE Biotherapeutics develops next-generation targeted oncology treatments, specifically plixorafenib, a novel BRAF inhibitor designed to treat patients with BRAF-altered solid tumors and other cancers. The company is a virtual biotech firm advancing plixorafenib through registration-intended clinical trials for patients with unaddressed mutations.